Iron Indices in Chronic Kidney Disease in the National Health and Nutritional Examination Survey 198

来源 :2013年中国肾性贫血治疗专家共识研讨会 | 被引量 : 0次 | 上传用户:xzh19870715
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background and objectives: Anemia is a common and early complication of nondialysis chronic kidney disease (CKD).One contributing factor is iron deficiency, which may be particularly problematic during erythropoietin replacement therapy.The aim of this study was to examine the prevalence of iron deficiency in nondialysis CKD.
其他文献
Background and Objectives: Instability of hemoglobin levels during epoetin therapy is a new problem in hemodialysis.We evaluated extent and correlates of time in target, that is, the time spent with h
会议
Background: Anaemia is a known risk factor for cardiovascular disease and treating anaemia in chronic kidney disease (CKD) may improve outcomes.However, little is known about the scope to improve prim
Objective-To determine whether recombinant human erythropoietin improves the quality of fife and exercise capacity of anaemic patients receiving haemodialysis.Design-A double blind, randomised, placeb
会议
Haemoglobin (Hgb) levels are known to be associated with numerous adverse outcomes in both chronic kidney disease (CKD) and non-CKD patients.This analysis evaluates the association of baseline haemogl
Anemia associated with chronic renal insufficiency (CRI) may have substantial clinical and public health importance, butlittle is known about its epidemiology.This study aims to quantify the relations
会议
Hemoglobin levels vary substantially over time in hemodialysis patients, and this variability may portend poor.outcomes.For a given patient, hemoglobin concentration over time can be described by abso
会议
Background and objectives: Anemia and hemoglobin (Hb) variability are associated with mortality in hemodialysis patients who are on erythropoiesis-stimulating agents (ESA).Our aim was to describe the
会议
Patients with CKD exhibit significant within-patient hemoglobin (Hb) level variability, especially with the use of erythropoiesis stimulating agents (ESAs) and iron.Analyses of dialysis cohorts in the
会议
National payment policies target a hemoglobin range of 11 to 12.5 g/dl for patients with ESRD.However, clinical complications and provider practices may contribute to wide fluctuations over time.This
会议
Background: Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intraveno